The global Dry Powder Inhaler Device market size was valued at US$ 852 million in 2024 and is forecast to a readjusted size of USD 1178 million by 2031 with a CAGR of 4.8% during review period.
A dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus.
GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, etc. are the key players in the global Dry Powder Inhaler Device market. Top 4 took up more than 30% of the global market.
From the view of region, USA have a larger consumption market share which account for about 35% of total share. Europe hold a market share of about 25%. In addition, Asia Pacific is also play important role in Global market.
Dry Powder Inhaler Device main application area is Asthma This sector hold a market share of over 80%. Then followed by the COPD.
According to the Segmentation of types, all the market of Dry Powder Inhaler Device can be divided as follows: Multi-dose, Single-dose.
This report is a detailed and comprehensive analysis for global Dry Powder Inhaler Device market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Dry Powder Inhaler Device market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Dry Powder Inhaler Device market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Dry Powder Inhaler Device market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Dry Powder Inhaler Device market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Dry Powder Inhaler Device
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Dry Powder Inhaler Device market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, 3M, Hovione, Mannkind, Mylan, Novartis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Dry Powder Inhaler Device market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Single Dose
Multi Dose
麻豆原创 segment by Application
Asthma
COPD
Others
Major players covered
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Chiesi
Cipla
3M
Hovione
Mannkind
Mylan
Novartis
Schering/Merck
Teva
Vectura
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Dry Powder Inhaler Device product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Dry Powder Inhaler Device, with price, sales quantity, revenue, and global market share of Dry Powder Inhaler Device from 2020 to 2025.
Chapter 3, the Dry Powder Inhaler Device competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Dry Powder Inhaler Device breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Dry Powder Inhaler Device market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Dry Powder Inhaler Device.
Chapter 14 and 15, to describe Dry Powder Inhaler Device sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Dry Powder Inhaler Device Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Single Dose
1.3.3 Multi Dose
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Dry Powder Inhaler Device Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Asthma
1.4.3 COPD
1.4.4 Others
1.5 Global Dry Powder Inhaler Device 麻豆原创 Size & Forecast
1.5.1 Global Dry Powder Inhaler Device Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Dry Powder Inhaler Device Sales Quantity (2020-2031)
1.5.3 Global Dry Powder Inhaler Device Average Price (2020-2031)
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 GlaxoSmithKline Details
2.1.2 GlaxoSmithKline Major Business
2.1.3 GlaxoSmithKline Dry Powder Inhaler Device Product and Services
2.1.4 GlaxoSmithKline Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 GlaxoSmithKline Recent Developments/Updates
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Dry Powder Inhaler Device Product and Services
2.2.4 AstraZeneca Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 AstraZeneca Recent Developments/Updates
2.3 Boehringer Ingelheim
2.3.1 Boehringer Ingelheim Details
2.3.2 Boehringer Ingelheim Major Business
2.3.3 Boehringer Ingelheim Dry Powder Inhaler Device Product and Services
2.3.4 Boehringer Ingelheim Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Boehringer Ingelheim Recent Developments/Updates
2.4 Chiesi
2.4.1 Chiesi Details
2.4.2 Chiesi Major Business
2.4.3 Chiesi Dry Powder Inhaler Device Product and Services
2.4.4 Chiesi Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Chiesi Recent Developments/Updates
2.5 Cipla
2.5.1 Cipla Details
2.5.2 Cipla Major Business
2.5.3 Cipla Dry Powder Inhaler Device Product and Services
2.5.4 Cipla Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Cipla Recent Developments/Updates
2.6 3M
2.6.1 3M Details
2.6.2 3M Major Business
2.6.3 3M Dry Powder Inhaler Device Product and Services
2.6.4 3M Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 3M Recent Developments/Updates
2.7 Hovione
2.7.1 Hovione Details
2.7.2 Hovione Major Business
2.7.3 Hovione Dry Powder Inhaler Device Product and Services
2.7.4 Hovione Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Hovione Recent Developments/Updates
2.8 Mannkind
2.8.1 Mannkind Details
2.8.2 Mannkind Major Business
2.8.3 Mannkind Dry Powder Inhaler Device Product and Services
2.8.4 Mannkind Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Mannkind Recent Developments/Updates
2.9 Mylan
2.9.1 Mylan Details
2.9.2 Mylan Major Business
2.9.3 Mylan Dry Powder Inhaler Device Product and Services
2.9.4 Mylan Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Mylan Recent Developments/Updates
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Dry Powder Inhaler Device Product and Services
2.10.4 Novartis Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Novartis Recent Developments/Updates
2.11 Schering/Merck
2.11.1 Schering/Merck Details
2.11.2 Schering/Merck Major Business
2.11.3 Schering/Merck Dry Powder Inhaler Device Product and Services
2.11.4 Schering/Merck Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Schering/Merck Recent Developments/Updates
2.12 Teva
2.12.1 Teva Details
2.12.2 Teva Major Business
2.12.3 Teva Dry Powder Inhaler Device Product and Services
2.12.4 Teva Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Teva Recent Developments/Updates
2.13 Vectura
2.13.1 Vectura Details
2.13.2 Vectura Major Business
2.13.3 Vectura Dry Powder Inhaler Device Product and Services
2.13.4 Vectura Dry Powder Inhaler Device Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Vectura Recent Developments/Updates
3 Competitive Environment: Dry Powder Inhaler Device by Manufacturer
3.1 Global Dry Powder Inhaler Device Sales Quantity by Manufacturer (2020-2025)
3.2 Global Dry Powder Inhaler Device Revenue by Manufacturer (2020-2025)
3.3 Global Dry Powder Inhaler Device Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Dry Powder Inhaler Device by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Dry Powder Inhaler Device Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Dry Powder Inhaler Device Manufacturer 麻豆原创 Share in 2024
3.5 Dry Powder Inhaler Device 麻豆原创: Overall Company Footprint Analysis
3.5.1 Dry Powder Inhaler Device 麻豆原创: Region Footprint
3.5.2 Dry Powder Inhaler Device 麻豆原创: Company Product Type Footprint
3.5.3 Dry Powder Inhaler Device 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Dry Powder Inhaler Device 麻豆原创 Size by Region
4.1.1 Global Dry Powder Inhaler Device Sales Quantity by Region (2020-2031)
4.1.2 Global Dry Powder Inhaler Device Consumption Value by Region (2020-2031)
4.1.3 Global Dry Powder Inhaler Device Average Price by Region (2020-2031)
4.2 North America Dry Powder Inhaler Device Consumption Value (2020-2031)
4.3 Europe Dry Powder Inhaler Device Consumption Value (2020-2031)
4.4 Asia-Pacific Dry Powder Inhaler Device Consumption Value (2020-2031)
4.5 South America Dry Powder Inhaler Device Consumption Value (2020-2031)
4.6 Middle East & Africa Dry Powder Inhaler Device Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Dry Powder Inhaler Device Sales Quantity by Type (2020-2031)
5.2 Global Dry Powder Inhaler Device Consumption Value by Type (2020-2031)
5.3 Global Dry Powder Inhaler Device Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Dry Powder Inhaler Device Sales Quantity by Application (2020-2031)
6.2 Global Dry Powder Inhaler Device Consumption Value by Application (2020-2031)
6.3 Global Dry Powder Inhaler Device Average Price by Application (2020-2031)
7 North America
7.1 North America Dry Powder Inhaler Device Sales Quantity by Type (2020-2031)
7.2 North America Dry Powder Inhaler Device Sales Quantity by Application (2020-2031)
7.3 North America Dry Powder Inhaler Device 麻豆原创 Size by Country
7.3.1 North America Dry Powder Inhaler Device Sales Quantity by Country (2020-2031)
7.3.2 North America Dry Powder Inhaler Device Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Dry Powder Inhaler Device Sales Quantity by Type (2020-2031)
8.2 Europe Dry Powder Inhaler Device Sales Quantity by Application (2020-2031)
8.3 Europe Dry Powder Inhaler Device 麻豆原创 Size by Country
8.3.1 Europe Dry Powder Inhaler Device Sales Quantity by Country (2020-2031)
8.3.2 Europe Dry Powder Inhaler Device Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Dry Powder Inhaler Device Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Dry Powder Inhaler Device Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Dry Powder Inhaler Device 麻豆原创 Size by Region
9.3.1 Asia-Pacific Dry Powder Inhaler Device Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Dry Powder Inhaler Device Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Dry Powder Inhaler Device Sales Quantity by Type (2020-2031)
10.2 South America Dry Powder Inhaler Device Sales Quantity by Application (2020-2031)
10.3 South America Dry Powder Inhaler Device 麻豆原创 Size by Country
10.3.1 South America Dry Powder Inhaler Device Sales Quantity by Country (2020-2031)
10.3.2 South America Dry Powder Inhaler Device Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Dry Powder Inhaler Device Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Dry Powder Inhaler Device Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Dry Powder Inhaler Device 麻豆原创 Size by Country
11.3.1 Middle East & Africa Dry Powder Inhaler Device Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Dry Powder Inhaler Device Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Dry Powder Inhaler Device 麻豆原创 Drivers
12.2 Dry Powder Inhaler Device 麻豆原创 Restraints
12.3 Dry Powder Inhaler Device Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Dry Powder Inhaler Device and Key Manufacturers
13.2 Manufacturing Costs Percentage of Dry Powder Inhaler Device
13.3 Dry Powder Inhaler Device Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Dry Powder Inhaler Device Typical Distributors
14.3 Dry Powder Inhaler Device Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Chiesi
Cipla
3M
Hovione
Mannkind
Mylan
Novartis
Schering/Merck
Teva
Vectura
听
听
*If Applicable.
